C-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy

International Journal of Cancer

Volumn 122, Issue 2, 2008, Pages 289-297

  Galan Moya, Eva M ^a   Hernandez Losa, Javier ^b   Aceves Luquero, Clara I ^a   De La Cruz Morcillo, Miguel A ^a   Ramírez Castillejo, Carmen ^a   Callejas Valera, Juan L ^a   Arriaga, Angel ^a   Aranburo, Antonio Fernandez ^c   Ramón Y Cajal, Santiago ^b   Gutkind, J Silvio ^d   Sánchez Prieto, Ricardo ^a,e  

^a UCLM   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Servicio de Oncología   (Spain)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

c Abl; Cisplatin; Imatinib mesylate; MKK6; p38 MAPK

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CISPLATIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CYCLOHEXIMIDE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE 6; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTEIN SYNTHESIS INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES;

EID: 36849004500     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23063     Document Type: Article

References (40)

1. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-4.
2. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-8.
3. Bulavin DV, Fornace AJ. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95-118.
4. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125-9.
5. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78.
6. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995;376:785-8.
7. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, WynshawBoris A, Kastan MB, Wang JYJ. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997;387:516-9.
8. Kharbanda S, Pandey P, Ren R, Mayer B, Zon L, Kufe D. c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-β-D-arabinofuranosylcytosine. J Biol Chem 1995;270:30278-81.
9. Sanchez-Arevalo LV, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernandez LJ, Parada CC, Galan Moya EM, Gayoso CJ, Melo JV, Cajal S, Sanchez-Prieto R. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/ Abl: implications in the cellular response to Ara-C. Biochem J 2005;387 (Part 1):231-8.
10. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
11. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr, Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
12. Truong T, Sun G, Doorly M, Wang JY, Schwartz MA. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci USA 2003;100: 10281-6.
13. Tsai KK, Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 2003;63:3418-24.
14. Losa JH, Cobo CP, Viniegra JG, Lobo VJSA, Cajal SRY, Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003;22:3998-4006.
15. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997;272:14041-4.
16. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16:533-40.
17. Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 2000;60:2464-72.
18. Cong F, Goff SP. C-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc Natl Acad Sci USA 1999;96:13819-24.
19. Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G, et al. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol 2000;20:4979-89.
20. Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JY, Howell SB, Christen RD. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997;57:3253-7.
21. Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D, Kharbanda S. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J Biol Chem 1996; 271:23775-9.
22. Agami R, Blandino G, Oren M, Shaul Y Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 1999;399: 809-13.
23. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399:814-17.
24. Sionov RV, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y, Ciechanover A, Haupt Y. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001;21:5869-78.
25. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
26. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002;277:32214-9.
27. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
28. Druker BJ. ST1571 (Gleevec (TM)) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14-S18.
29. Fukuhara S, Marinissen MJ, Chiariello M, Gutkind JS. Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Gα q and Gα 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras AND Rho-independent pathway. J Biol Chem 2000;275:21730-6.
30. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002;21:974-9.
31. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007;251:1-16.
32. Choi SY, Kim MJ, Kang CM, Bae S, Cho CK, Soh JW, Kim JH, Kang S, Chung HY, Lee YS, Lee SJ. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J Biol Chem 2006;281:7049-59.
33. Buschbeck M, Hofbauer S, Croce LD, Keri G, Ullrich A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 2005;6:63-9.
34. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006;106:366-74.
35. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 2002;21:3715-27.
36. Chen X, Zhang J, Lee J, Lin PS, Ford JM, Zheng N, Zhou P. A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell 2006;22:489-99.
37. -/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 1995;9:1505-17.
38. -/- mutant mice. Genes Dev 1997;11:2835-44.
39. Yu CR, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/ Abl-expressing human leukemia cells. Cancer Res 2002;62:188-99.
40. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004;279:25345-52.